Secondary Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease Inform Gene Therapy Approaches

Affiliations

¹ Roland Meisel MD, Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.

Comment

Roland Meisel. J Clin Oncol. 2023.

. 2023 Jun 10;41(17):3272-3273.

doi: 10.1200/JCO.23.00403. Epub 2023 Apr 12.

¹ Roland Meisel MD, Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.

No abstract available

Comment in

Reply to R. Meisel.
Eapen M, Brazaukas R. Eapen M, et al. J Clin Oncol. 2023 Jun 10;41(17):3273-3274. doi: 10.1200/JCO.23.00508. Epub 2023 Apr 12. J Clin Oncol. 2023. PMID: 37043706 Free PMC article. No abstract available.

Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, London WB, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, Horowitz MM. Eapen M, et al. J Clin Oncol. 2023 Apr 20;41(12):2227-2237. doi: 10.1200/JCO.22.01203. Epub 2023 Jan 9. J Clin Oncol. 2023. PMID: 36623245 Free PMC article.